Literature DB >> 6357433

Cytotoxic effector cell function at different stages of human monocyte-macrophage maturation.

R Andreesen, J Osterholz, K J Bross, A Schulz, G A Luckenbach, G W Löhr.   

Abstract

Human blood-borne monocytes were cultured for up to 22 days on disposable Teflon foils. Within 8 days, these monocytes developed into mature macrophages. At various stages of differentiation, the cells were recovered from the hydrophobic membrane and were assayed for typical monocyte-macrophage enzymes and morphology, binding of monoclonal antibodies (OKM1, OKla1), Fc and transferrin receptors, phagocytic activity, lysozyme production, and ability to inhibit the growth of an allogeneic tumor target cell line (U937). A significant antitumor activity of mature macrophages was found, which developed along with the differentiation of the monocyte precursor cells. In addition, cytotoxic effector macrophages could be activated by lymphokine-rich medium and synthetic alkyl-lysophospholipids. After density gradient separation, light cells (less than 1.05 and less than 1.06 g/ml) showed enhanced cytotoxicity, whereas cells from the dense fraction (greater than 1.06 g/ml) with low base-line activity could be best activated for cytotoxicity by lymphokines. If monocyte-macrophages are involved in a natural surveillance mechanism, our results may indicate the importance of unimpaired macrophage maturation to generate effective host defense against tumor development.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6357433

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Degradation of Chlamydia pneumoniae by peripheral blood monocytic cells.

Authors:  Katerina Wolf; Elizabeth Fischer; Ted Hackstadt
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

2.  Proceedings of the British Thoracic Society, Scottish Thoracic Society and Thoracic Society of Australia. The 1987 summer meeting. 1-3 July, Edinburgh. Abstracts.

Authors: 
Journal:  Thorax       Date:  1987-09       Impact factor: 9.139

3.  Human macrophage maturation and heterogeneity: restricted expression of late differentiation antigens in situ.

Authors:  R Andreesen; S Gadd; U Costabel; H G Leser; V Speth; B Cesnik; R C Atkins
Journal:  Cell Tissue Res       Date:  1988-08       Impact factor: 5.249

4.  Role of interferon gamma and tumour necrosis factor alpha in monocyte-mediated cytostasis and cytotoxicity against a human histiocytic lymphoma cell line.

Authors:  A A van de Loosdrecht; G J Ossenkoppele; R H Beelen; M G Broekhoven; M M Langenhuijsen
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

5.  Human macrophages can express the Hodgkin's cell-associated antigen Ki-1 (CD30).

Authors:  R Andreesen; W Brugger; G W Löhr; K J Bross
Journal:  Am J Pathol       Date:  1989-01       Impact factor: 4.307

6.  Expression of transferrin receptors and intracellular ferritin during terminal differentiation of human monocytes.

Authors:  R Andreesen; J Osterholz; H Bodemann; K J Bross; U Costabel; G W Löhr
Journal:  Blut       Date:  1984-09

7.  Differential effects of ether lipids on the activity and secretion of interleukin-1 and interleukin-2.

Authors:  R Andreesen; V Giese
Journal:  Lipids       Date:  1987-11       Impact factor: 1.880

8.  Interactions between human macrophages and tumor cells in three-dimensional cultures.

Authors:  R Audran; L Dazord; L Toujas
Journal:  Cancer Immunol Immunother       Date:  1994-11       Impact factor: 6.968

9.  Human macrophage maturation in vitro: expression of functional transferrin binding sites of high affinity.

Authors:  R Andreesen; R G Sephton; S Gadd; R C Atkins; S De Abrew
Journal:  Blut       Date:  1988-08

Review 10.  Dysregulated Expression of Glycolipids in Tumor Cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic Agents.

Authors:  Jose Luis Daniotti; Ricardo D Lardone; Aldo A Vilcaes
Journal:  Front Oncol       Date:  2016-01-07       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.